Compare · TMO vs VICR
TMO vs VICR
Side-by-side comparison of Thermo Fisher Scientific Inc (TMO) and Vicor Corporation (VICR): market cap, price performance, sector, and recent activity on the wire.
Summary
- TMO operates in Industrials, while VICR operates in Technology - the two are in different parts of the market.
- TMO is the larger of the two at $174.52B, about 13.9x VICR ($12.53B).
- Over the past year, TMO is up 14.9% and VICR is up 500.0% - VICR leads by 485.1 points.
- VICR has been more active in the news (18 items in the past 4 weeks vs 17 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 13 for VICR).
- Company
- Thermo Fisher Scientific Inc
- Vicor Corporation
- Price
- $469.56-0.67%
- $275.10+1.78%
- Market cap
- $174.52B
- $12.53B
- 1M return
- -1.03%
- +5.41%
- 1Y return
- +14.92%
- +500.00%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 17
- 18
- Recent ratings
- 25
- 13
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Vicor Corporation
Vicor Corporation, together with its subsidiaries, designs, develops, manufactures, and markets modular power components and power systems for converting electrical power in the United States, Europe, the Asia Pacific, and internationally. The company offers a range of brick-format DC-DC converters; complementary components; and input and output voltage, and output power products, as well as electrical and mechanical accessories. It also provides custom power systems solutions. The company serves independent manufacturers of electronic devices, original equipment manufacturers, and their contract manufacturers in the aerospace and aviation, defense electronics, industrial automation and equipment, instrumentation, test equipment, solid state lighting, telecommunications and networking infrastructure, and vehicles and transportation markets. Vicor Corporation was founded in 1981 and is headquartered in Andover, Massachusetts.
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)
Latest VICR
- Corp. VP-Eng., Pwr Syst. Crilly Sean sold $706,293 worth of shares (2,500 units at $282.52), decreasing direct ownership by 26% to 7,229 units (SEC Form 4)
- Chairman and CEO Vinciarelli Patrizio sold $5,527,953 worth of shares (20,000 units at $276.40) as part of a pre-agreed trading plan, decreasing direct ownership by 0.23% to 8,708,090 units (SEC Form 4)
- Director Eichten Estia J gifted 90,000 shares, decreasing direct ownership by 48% to 98,838 units (SEC Form 4)
- Chairman and CEO Vinciarelli Patrizio sold $6,237,098 worth of shares (20,000 units at $311.85) as part of a pre-agreed trading plan, decreasing direct ownership by 0.23% to 8,728,090 units (SEC Form 4)
- Chairman and CEO Vinciarelli Patrizio sold $6,603,842 worth of shares (20,000 units at $330.19) as part of a pre-agreed trading plan, decreasing direct ownership by 0.23% to 8,748,090 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Vicor Corporation
- Chairman and CEO Vinciarelli Patrizio sold $6,541,526 worth of shares (20,000 units at $327.08) as part of a pre-agreed trading plan, decreasing direct ownership by 0.23% to 8,768,090 units (SEC Form 4)
- Chairman and CEO Vinciarelli Patrizio sold $6,437,096 worth of shares (20,000 units at $321.85) as part of a pre-agreed trading plan, decreasing direct ownership by 0.23% to 8,788,090 units (SEC Form 4)
- CFO, Treasurer, Secretary Schmidt James F exercised 5,000 shares at a strike of $93.33 and sold $1,609,125 worth of shares (5,000 units at $321.83) as part of a pre-agreed trading plan (SEC Form 4)
- VP Global Sales & Marketing Davies Philip D exercised 3,072 shares at a strike of $30.98 and sold $988,240 worth of shares (3,072 units at $321.69) as part of a pre-agreed trading plan (SEC Form 4)